Open Access

Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4‑ALK fusion: A case report

  • Authors:
    • Mingting Wang
    • Yifan Gong
    • Yun Cheng
    • Lei Yang
    • Wenhui Wang
    • Xiaolin Lei
  • View Affiliations

  • Published online on: August 17, 2022     https://doi.org/10.3892/ol.2022.13463
  • Article Number: 343
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a rare form of poorly differentiated non‑small‑cell lung cancer that is prone to distant metastases. PSC is therapeutically challenging, with low sensitivity to conventional radiotherapy and a poor overall prognosis. The present study reported on the case of a 29‑year‑old male non‑smoker diagnosed with both PSC and lung adenocarcinoma; the cancer had a complex etiology and rapidly metastasized after surgery. The patient presented with an EML4‑ALK gene fusion in both tumors with high programmed death ligand‑1 (PD‑L1) expression. After initial treatment failure, Alectinib, Anlotinib and Tirelizumab were combined, which rapidly resolved the patient's symptoms and led to partial remission of disease at 6 weeks and effective control of the disease 7 months into the treatment. This case exemplifies the efficacy of combining targeted chemotherapy with immunotherapy for patients with PSC. Furthermore, this outcome suggests the usefulness of genetic testing and monitoring PD‑L1 expression to identify patients with PSC who may be candidates likely to respond to this combined therapeutic regimen. The present study provides evidence of the success of a novel therapeutic strategy for patients with PSC.
View Figures
View References

Related Articles

Journal Cover

October-2022
Volume 24 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang M, Gong Y, Cheng Y, Yang L, Wang W and Lei X: Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4‑ALK fusion: A case report. Oncol Lett 24: 343, 2022
APA
Wang, M., Gong, Y., Cheng, Y., Yang, L., Wang, W., & Lei, X. (2022). Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4‑ALK fusion: A case report. Oncology Letters, 24, 343. https://doi.org/10.3892/ol.2022.13463
MLA
Wang, M., Gong, Y., Cheng, Y., Yang, L., Wang, W., Lei, X."Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4‑ALK fusion: A case report". Oncology Letters 24.4 (2022): 343.
Chicago
Wang, M., Gong, Y., Cheng, Y., Yang, L., Wang, W., Lei, X."Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4‑ALK fusion: A case report". Oncology Letters 24, no. 4 (2022): 343. https://doi.org/10.3892/ol.2022.13463